LUCD Stock Price, Lucid Diagnostics Inc. Quote, Chart

Market Summary

USD0.95-0.08

Market Closed

-7.77%

LUCD Stock Price

View Fullscreen

LUCD RSI Chart

LUCD Valuation

Market Cap

45.8M

Price/Earnings (Trailing)

-0.87

Price/Sales (Trailing)

18.88

EV/EBITDA

-0.54

Price/Free Cashflow

-1.4

LUCD Price/Sales (Trailing)

LUCD Profitability

Operating Margin

75.91%

EBT Margin

-2169.11%

Return on Equity

2.3K%

Return on Assets

-193.13%

Free Cashflow Yield

-71.56%

LUCD Fundamentals

LUCD Revenue

Revenue (TTM)

2.4M

Rev. Growth (Yr)

828.57%

Rev. Growth (Qtr)

32.82%

LUCD Earnings

Earnings (TTM)

-52.7M

Earnings Growth (Yr)

27.45%

Earnings Growth (Qtr)

23.78%

Breaking Down LUCD Revenue

Last 7 days

8.0%

Last 30 days

5.6%

Last 90 days

-25.2%

Trailing 12 Months

-36.7%

How does LUCD drawdown profile look like?

LUCD Financial Health

Current Ratio

0.75

LUCD Investor Care

Shares Dilution (1Y)

15.55%

Diluted EPS (TTM)

-1.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	634.0K	793.0K	1.5M	2.4M
2022	533.0K	481.0K	429.0K	377.0K
2021	0	0	0	585.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lucid Diagnostics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	pavmed inc.	sold	-	-	-3,331,750	-
Jan 26, 2024	pavmed inc.	acquired	4,675,470	1.4033	3,331,770	-
Sep 26, 2023	lapidus stanley	sold	-43,173	1.45134	-29,747	-
Sep 25, 2023	lapidus stanley	sold	-286	1.43	-200	-
Sep 21, 2023	lapidus stanley	sold	-144	1.44	-100	-
Sep 20, 2023	lapidus stanley	sold	-5,530	1.44892	-3,817	-
Nov 30, 2022	pavmed inc.	acquired	6,474,470	1.91823	3,375,240	-
Nov 30, 2022	pavmed inc.	acquired	6,474,460	1.91823	3,375,230	-

Which funds bought or sold LUCD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-1,079	-	-%
May 03, 2024	Geneos Wealth Management Inc.	unchanged	-	-20,310	27,419	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Allworth Financial LP	new	-	128	128	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	new	-	40.00	40.00	-%
Apr 22, 2024	Byrne Asset Management LLC	sold off	-100	-9,518	-	-%
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	new	-	1.00	1.00	-%
Apr 05, 2024	CWM, LLC	new	-	1,000	1,000	-%
Apr 02, 2024	M&R CAPITAL MANAGEMENT INC	new	-	20.00	20.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.1	87,759	468,671	-%

Are Funds Buying or Selling LUCD?

Are funds buying LUCD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUCD

No. of Funds

Unveiling Lucid Diagnostics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	pavmed inc.	65.2%	31,302,444	SC 13D/A
Feb 14, 2024	ayrton capital llc	9.9%	1,163,629	SC 13G
Feb 02, 2024	pavmed inc.	72.2%	34,634,191	SC 13D/A
Mar 24, 2023	ayrton capital llc	4.87%	2,222,222	SC 13G/A
Mar 23, 2023	ayrton capital llc	9.99%	4,816,167	SC 13G
Dec 02, 2022	pavmed inc.	73.7%	31,302,420	SC 13D/A

Recent SEC filings of Lucid Diagnostics Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Lucid Diagnostics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.8B	2.7B	-17.82%	-26.90%	-12.29	2.93	-4.68%	82.43%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	166.7M	11.74%	12.93%	-5.12	2.54	6.67%	-456.34%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Lucid Diagnostics Inc. News

Latest updates

Lucid Diagnostics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	32.8%	1,040,000	783,000	159,000	446,000	112,000	76,000	-	189,000	166,500	144,000
Cost Of Revenue	-	-	-	-	-	-	-	-	369,000	-	144,273
Gross Profit	-	-	-	-	-	112,000	76,000	-	-180,000	-	200,000
Operating Expenses	4.9%	12,493,000	11,911,000	11,743,000	14,763,000	15,087,000	14,453,000	14,628,000	12,460,000	11,540,500	6,710,000
S&GA Expenses	14.9%	4,408,000	3,837,000	4,032,000	4,127,000	5,013,000	3,930,000	3,873,000	3,318,000	2,632,500	918,000
R&D Expenses	6.7%	1,723,000	1,615,000	1,827,000	2,282,000	2,337,000	2,704,000	3,440,000	2,881,000	3,481,500	2,190,000
EBITDA Margin	-Infinity%	-20.49	-	-13.51	-14.88	-15.00	-17.70	-20.85	-26.83	-46.86	-
Interest Expenses	-92.6%	11,000	149,000	223,000	33,000	-	-	-	-	-	447,000
Earnings Before Taxes	23.8%	-10,830,000	-14,208,000	-11,381,000	-16,247,000	-14,928,000	-14,349,000	-14,624,000	-12,270,000	-11,305,500	-6,957,000
EBT Margin	-81.0%	-21.69	-11.98	-14.12	-15.54	-15.54	-18.39	-21.51	-27.34	-48.00	-
Net Income	23.8%	-10,830,000	-14,208,000	-11,381,000	-16,247,000	-14,928,000	-14,349,000	-14,624,000	-12,270,000	-11,305,500	-6,957,000
Net Income Margin	-81.0%	-21.69	-11.98	-14.12	-15.54	-15.54	-18.39	-21.51	-27.34	-48.00	-
Free Cashflow	-13.4%	-9,979,000	-8,798,000	-7,029,000	-7,062,000	-4,258,000	-7,346,000	-15,357,000	-5,924,000	-10,701,000	-2,210,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-18.0%	27.00	33.00	42.00	49.00	33.00	38.00	45.00	62.00	59.00	3.00	2.00
Current Assets	-19.2%	22.00	27.00	36.00	42.00	24.00	30.00	36.00	52.00	57.00	3.00	1.00
Cash Equivalents	-21.4%	19.00	24.00	33.00	40.00	22.00	27.00	33.00	48.00	54.00	0.00	0.00
Inventory	-	0.00	-	-	-	0.00	-	-	-	-	-	-
Net PPE	3.9%	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	-	-
Liabilities	-3.6%	30.00	31.00	27.00	24.00	9.00	11.00	9.00	16.00	4.00	27.00	16.00
Current Liabilities	-2.8%	29.00	30.00	27.00	23.00	8.00	10.00	8.00	14.00	4.00	-	-
Shareholder's Equity	-190.4%	-2.31	3.00	15.00	25.00	23.00	28.00	36.00	46.00	55.00	-	-
Retained Earnings	-7.7%	-150	-139	-125	-114	-98.07	-83.15	-68.80	-54.17	-41.90	-30.60	-13.83
Additional Paid-In Capital	0.7%	130	129	127	126	121	111	105	101	97.00	6.00	0.00
Shares Outstanding	0%	42.00	42.00	42.00	42.00	41.00	36.00	35.00	35.00	35.00	14.00	14.00
Float	-	-	-	14.00	-	-	-	19.00	-	-	81.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-13.4%	-9,962	-8,781	-7,012	-7,045	-4,258	-6,346	-13,305	-5,776	-9,877	-2,182	-2,294	-3,315	-	-
Share Based Compensation	-27.5%	748	1,032	1,165	2,817	3,488	3,280	3,554	3,537	-	-	-	-	-	-
Cashflow From Investing	-1150.0%	-175	-14.00	-15.00	-17.00	-203	-1,321	-2,436	-148	-824	-28.00	-1.00	-9.00	-	-
Cashflow From Financing	1718.2%	5,000	275	75.00	24,110	1.00	1,922	501	187	64,336	-	4,439	3,300	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LUCD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Income Statement [Abstract]

Revenue

$ 2,428

$ 377

Operating expenses:

Cost of revenue

5,979

3,614

Sales and marketing

16,404

16,134

General and administrative

19,254

23,974

Amortization of acquired intangible assets

2,021

1,649

Research and development

7,252

11,257

Total operating expenses

50,910

56,628

Operating loss

(48,482)

(56,251)

Other income (expense):

Interest income

424

88

Interest expense

(416)

(8)

Change in fair value - Senior Secured Convertible Note

(2,980)

Loss on issue and offering costs - Senior Secured Convertible Note

(1,186)

Debt extinguishments loss - Senior Secured Convertible Note

(26)

Other income (expense), net

(4,184)

80

Loss before provision for income tax

(52,666)

(56,171)

Provision for income taxes

Net loss

$ (52,666)

$ (56,171)

Net loss per share - basic

^[1]

$ (1.26)

$ (1.55)

Net loss per share - diluted

^[1]

$ (1.26)

$ (1.55)

Weighted average common shares outstanding, basic

41,756,129

36,172,421

Weighted average common shares outstanding, diluted

41,756,129

36,172,421

[1]

- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

LUCD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 18,896	$ 22,474
Accounts receivable	45	17
Inventory	278	111
Prepaid expenses, deposits, and other current assets	2,854	1,754
Total current assets	22,073	24,356
Fixed assets, net	1,334	1,592
Operating lease right-of-use assets	1,307	2,008
Intangible assets, net	1,424	3,445
Other assets	1,132	1,108
Total assets	27,270	32,509
Current liabilities:
Accounts payable	1,146	1,056
Accrued expenses and other current liabilities	3,841	1,447
Operating lease liabilities, current portion	1,106	962
Senior Secured Convertible Note - at fair value	13,950
Due To: PAVmed Inc. - MSA Fee and operating expenses	9,339	4,960
Total current liabilities	29,382	8,425
Operating lease liabilities, less current portion	199	1,037
Total liabilities	29,581	9,462
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series A and Series A-1 Convertible Preferred Stock, issued and outstanding 18,625 at December 31, 2023 and no shares issued and outstanding at December 31, 2022	18,625
Common stock, $0.001 par value, 200,000,000 shares authorized; 42,329,864 and 40,518,792 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	42	41
Additional paid-in capital	129,763	121,081
Accumulated deficit	(150,741)	(98,075)
Total Stockholders’ Equity (Deficit)	(2,311)	23,047
Total Liabilities and Stockholders’ Equity (Deficit)	$ 27,270	$ 32,509

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

0

CEO	Dr. Lishan Aklog M.D.
WEBSITE	luciddx.com
INDUSTRY	Medical Instruments & Supplies

Lucid Diagnostics Inc. Frequently Asked Questions

What is the ticker symbol for Lucid Diagnostics Inc.? What does LUCD stand for in stocks?

LUCD is the stock ticker symbol of Lucid Diagnostics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lucid Diagnostics Inc. (LUCD)?

As of Wed May 08 2024, market cap of Lucid Diagnostics Inc. is 45.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUCD stock?

You can check LUCD's fair value in chart for subscribers.

What is the fair value of LUCD stock?

You can check LUCD's fair value in chart for subscribers. The fair value of Lucid Diagnostics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lucid Diagnostics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUCD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lucid Diagnostics Inc. a good stock to buy?

The fair value guage provides a quick view whether LUCD is over valued or under valued. Whether Lucid Diagnostics Inc. is cheap or expensive depends on the assumptions which impact Lucid Diagnostics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUCD.

What is Lucid Diagnostics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, LUCD's PE ratio (Price to Earnings) is -0.87 and Price to Sales (PS) ratio is 18.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUCD PE ratio will change depending on the future growth rate expectations of investors.